Atrium Therapeutics Inc
RNA
NASDAQ
Biotechnology
$12.84
USD
+0.51 (+4.14%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $209.37M
Volume 176.1K
Revenue
$36.82M
TTM
+312.4%
YoY
Gross Margin
100%
TTM
0.0%
YoY
Net Income
$-585.49M
TTM
-58.6%
YoY
Operating Cash Flow
$-556.75M
TTM
-56.7%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 |
|---|---|---|---|---|---|
Revenue | 1.6 | 3.8 | 12.5 | 0.9 | 19.6 |
YoY Growth | -55.6% | +88.1% | +434.0% | -71.1% | +1148.3% |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 1.6 | 3.8 | 12.5 | 0.9 | 19.6 |
Selling, General & Administrative | 33.6 | 36.9 | 46.3 | 88.7 | 20.3 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 133.1 | 175.0 | 201.3 | 255.3 | 36.9 |
Operating Income | -131.5 | -171.1 | -188.8 | -254.5 | -17.3 |
EBITDA | -130.7 | -170.3 | -187.8 | -253.0 | -17.1 |
Other Income / Expense | -0.4 | -0.7 | -0.4 | -0.5 | 0.6 |
Total Other Income / Expense | 15.7 | 13.8 | 14.4 | 17.4 | 0.6 |
Income Before Income Taxes | -115.8 | -157.3 | -174.4 | -237.1 | -16.6 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -115.8 | -157.3 | -174.4 | -237.1 | -16.6 |
Consolidated Net Income / Loss | -115.8 | -157.3 | -174.4 | -237.1 | -16.6 |
Net Income Attributable to Common Shareholders | -115.8 | -157.3 | -174.4 | -237.1 | -16.6 |
Basic EPS | -$0.90 | -$1.21 | -$1.27 | -$1.54 | -$0.97 |
Diluted EPS | -$0.90 | -$1.21 | -$1.27 | -$1.54 | -$0.97 |
Basic Shares Outstanding | 129.2M | 129.6M | 137.9M | 154.1M | 17.1M |
Diluted Shares Outstanding | 129.2M | 129.6M | 137.9M | 154.1M | 17.1M |